Elite Pharmaceuticals (ELTP) reported $149M in revenue for fiscal 2025, +77.1% year on year. That ranks #2793 by revenue among 2853 SEC filers and #309 in Healthcare. Net income was $44.9M, a net margin of 30.1%. Revenue has grown 45.4% a year on average since 2017 ($7.5M then). The fiscal 2025 balance sheet shows $126M in total assets and $21.6M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $149M | +77.1% | FY20252026-03-31 |
| Gross profitGrossProfit | $75.0M | +87.2% | FY20252026-03-31 |
| Operating incomeOperatingIncomeLoss | $49.1M | +150.6% | FY20252026-03-31 |
| Net incomeNetIncomeLoss | $44.9M | +$49.2M | FY20252026-03-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $23.7M | +218.5% | FY20252026-03-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $925,626 | −43.0% | FY20252026-03-31 |
| Total assetsAssets | $126M | +39.3% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $80.3M | +120.4% | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $21.6M | +146.6% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q2 20262026-06-30 | $32.4M | $5.9M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Elite Pharmaceuticals Inc
- Ticker
- ELTP
- Exchange
- OTC
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 03-31
- CIK
- 0001053369
Filings
- 10-QAug 13, 2026Open filing →
- 10-KJun 29, 2026Open filing →
- 10-QFeb 17, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Airsculpt TechnologiesAIRS | $152M | −$11.7M |
| MacrogenicsMGNX | $150M | −$74,620 |
| NeuroneticsSTIM | $149M | −$39.0M |
| Elite PharmaceuticalsELTP | $149M | $44.9M |
| GrailGRAL | $147M | −$408M |
| Cronos GroupCRON | $147M | −$2.9M |
| Karyopharm TherapeuticsKPTI | $146M | −$196M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Elite Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/elite-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Elite Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/elite-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-elite-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Elite Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/elite-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001493152-26-031070 · June 29, 2026
{{cite web |title=Elite Pharmaceuticals — Key figures — 10-K (0001493152-26-031070) |url=https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-06-29}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.